<?xml version="1.0" encoding="UTF-8"?>
<p>In December 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine (Pfizer, Inc; Philadelphia, Pennsylvania). This vaccine is a lipid nanoparticle-formulated nucleoside-modified mRNA vaccine encoding the prefusion Spike glycoprotein of SARS-CoV-2.</p>
